TG THERAPEUTICS, INC. Dilutive Share Adjustment
TG THERAPEUTICS, INC. (TGTX) reported Dilutive Share Adjustment of 15.51 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment · last filed 2026-08-05
- TG THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2026-06-30 was 15.51M shares, a 1.95% decline year-over-year.
- TG THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2026-03-31 was 15.62M shares, a 2.91% decline year-over-year.
- TG THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-12-31 was 20.90M shares, a 39.31% increase year-over-year.
- TG THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-09-30 was 15.58M shares, a 0.20% decline year-over-year.
- TG THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2025 was 17.10M shares, a 13.83% increase from fiscal 2024.
- TG THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2024 was 15.02M shares, a 129.17% increase from fiscal 2023.
- TG THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2023 was 6.55M shares.
- TG THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2022 was 0.00 shares.
| Period end | Weighted Average Number Diluted Shares Outstanding Adjustment 3 month | Weighted Average Number Diluted Shares Outstanding Adjustment 6 month | Weighted Average Number Diluted Shares Outstanding Adjustment 9 month | Weighted Average Number Diluted Shares Outstanding Adjustment 12 month |
|---|---|---|---|---|
| 2026-06-30 | 15.51M shares 10-Q · filed 2026-08-05 | 15.57M shares 10-Q · filed 2026-08-05 | 17.34M shares derived: average of 3 quarters · filed 2026-08-05 | 16.90M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 15.62M shares 10-Q · filed 2026-05-06 | 18.26M shares derived: average of 2 quarters · filed 2026-05-06 | 17.37M shares derived: average of 3 quarters · filed 2026-05-06 | 16.98M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 20.90M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 18.24M shares derived: average of 2 quarters · filed 2026-02-27 | 17.43M shares derived: average of 3 quarters · filed 2026-08-05 | 17.10M shares 10-K · filed 2026-02-27 |
| 2025-09-30 | 15.58M shares 10-Q · filed 2025-11-05 | 15.70M shares derived: average of 2 quarters · filed 2026-08-05 | 15.83M shares 10-Q · filed 2025-11-05 | 15.62M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 15.82M shares 10-Q · filed 2026-08-05 | 15.82M shares 10-Q · filed 2026-08-05 | 15.64M shares derived: average of 3 quarters · filed 2026-08-05 | 15.63M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 16.09M shares 10-Q · filed 2026-05-06 | 15.55M shares derived: average of 2 quarters · filed 2026-05-06 | 15.57M shares derived: average of 3 quarters · filed 2026-05-06 | 15.35M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 15.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 15.31M shares derived: average of 2 quarters · filed 2026-02-27 | 15.10M shares derived: average of 3 quarters · filed 2026-02-27 | 15.02M shares 10-K · filed 2026-02-27 |
| 2024-09-30 | 15.61M shares 10-Q · filed 2025-11-05 | 15.15M shares derived: average of 2 quarters · filed 2025-11-05 | 15.02M shares 10-Q · filed 2025-11-05 | 10.84M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | 14.70M shares 10-Q · filed 2025-08-08 | 0.00 shares 10-Q · filed 2025-08-08 | 9.26M shares derived: average of 3 quarters · filed 2026-02-27 | 10.19M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-09 | 6.54M shares derived: average of 2 quarters · filed 2026-02-27 | 8.69M shares derived: average of 3 quarters · filed 2026-02-27 | 6.52M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | 13.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 13.04M shares derived: average of 2 quarters · filed 2026-02-27 | 8.69M shares derived: average of 3 quarters · filed 2026-02-27 | 6.55M shares 10-K · filed 2026-02-27 |
| 2023-09-30 | 13.00M shares 10-Q · filed 2024-11-07 | 6.50M shares derived: average of 2 quarters · filed 2024-11-07 | 4.38M shares 10-Q · filed 2024-11-07 | |
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-09 | 0.00 shares 10-Q · filed 2024-08-09 | ||
| 2022-12-31 | 0.00 shares 10-K · filed 2025-03-03 | |||
| 2021-12-31 | 0.00 shares 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |